Systemic lupus erythematosus as a multidisciplinary problem (clinical case)
DOI:
https://doi.org/10.26641/2307-0404.2025.2.333835Keywords:
systemic lupus erythematosus, lupus crisis, lupus nephritis, renal failureAbstract
Systemic lupus erythematosus (SLE) is a prognostically unfavorable systemic connective tissue disease with heterogeneous clinical manifestations, development of complications, and an unpredictable wave-like course, which complicates the diagnosis of this pathology. The relevance of this clinical case is determined by a number of features: the debut of SLE with isolated kidney damage, an 11-year delay in the date of diagnosis, and the occurrence of an extremely rare complication – lupus crisis (LC), which became fatal for the patient. The aim of the work: to analyze a clinical case as unique in terms of the features of the debut and clinical course of systemic lupus erythematosus, which has become a multidisciplinary problem, to highlight the reasons for the delay in diagnosis verification, to assess, in dynamics, the effectiveness of the prescribed treatment and to report on the development of a multiorgan lupus crisis. The article analyzes data from the medical documents of a 31-year-old inpatient. An illustrative clinical case of SLE, which debuted with glomerulonephritis at the age of 16, 11 years before the appearance of specific clinical symptoms that met the criteria of the American College of Rheumatology and the European League Against Rheumatism 2019, is presented. The level of immunological indicators specific for SLE – antinuclear antibodies to double-stranded deoxyribonucleic acid increased in the patient in 2023, i.e. 4 years later. The patient’s refusal of nephro biopsy, starting from the debut of the disease and from pathogenetic therapy at the stage of diagnosis and during the next 4 years. led to increased SLE activity, frequent relapses with the development of polymorbid pathology and, incompatible with life, multiorgan lupus crisis. The article describes in detail the dynamics of clinical manifestations of SLE and LC. The stages of diagnostic search, features of differential diagnosis and treatment of SLE and LC are discussed on the example of a clinical case. Based on the results of a review of the medical literature, analysis of articles, databases PubMed, SCOPUS, Web of Science, MedScape, the current state of the problem is highlighted, literature data on the incidence, features of the clinical course, diagnosis and treatment of SLE, its complications are summarized. The description of the clinical case, analysis of the literature is an addition to modern information about the possible clinical manifestations and consequences of SLE with the development of a severe, extremely rare complication – lupus crisis.
References
Hoi A, Igel T, Mok CC, Arnaud L. Systemic lupus erythematosus. Lancet. 2024;403(10441):2326-38. doi: https://doi.org/10.1016/S0140-6736(24)00398-2
Kant S, Kronbichler A, Sharma P, Geetha D. Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. Am J Kidney Dis. 2022;79(4):582-600. doi: https://doi.org/10.1053/j.ajkd.2021.07.019
Ameer MA, Chaudhry H, Mushtaq J, Khan OS, Babar M, Hashim T, et al. Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus. 2022;14(10):e30330. doi: https://doi.org/10.7759/cureus.30330
Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review. JAMA. 2024;331(17):1480-91. doi: https://doi.org/10.1001/jama.2024.2315
Davidenko K. [Lupus nephritis: diagnosis and treatment]. Ukr Med J [Internet]. 2019 [cited 2024 Dec 13];5(133 Pt 1):1-3. Ukrainian. Available from: https://umj.com.ua/uk/publikatsia-162408-vovchakovij-nefrit-diagnostika-ta-likuvannya
Protsenko HO, Dubas VV. [Systemic lupus erythematosus: the state of the problem in Ukraine and the world]. Ukr J Rheumatol. 2020;4(82):25-34. Ukrainian. doi: https://doi.org/10.32471/rheumatology.2707-6970.82.15749
Christou EAA, Banos A, Kosmara D, Bertsias GK, Boumpas DT. Sexual dimorphism in SLE: above and beyond sex hormones. Lupus. 2019;28(1):3-10. doi: https://doi.org/10.1177/0961203318815768
Dzhus MB, Ivashkivskyi OI, Karasevska TA, Potomka RA, Novytska AL, Mikuksts VYa, et al. [Soft tissue calcifications in systemic lupus erythematosus. A clinical case and literature review]. Ukr J Rheumatol. 2021;1(83):64-73. Ukrainian. doi: https://doi.org/10.32471/rheumatology.2707-6970.83.16006
Protsenko HO, Dubas VV, Uzun SV, Tsokalo YaV, Zbarashchenko-Hasan MI. [Cutaneous manifestations in systemic lupus erythematosus (a case report)]. Ukr J Rheumatol. 2020;4(82):25-34. Ukrainian. doi: https://doi.org/10.32471/rheumatology.2707-6970.91.17654
Gilcrease W, Manfredi L, Sciascia S, Ricceri F. From Multimorbidity to Network Medicine in Patients with Rheumatic Diseases. Rheumatol Ther. 2025 Feb;12(1):1-24.
doi: https://doi.org/10.1007/s40744-024-00724-8
Zhdan VM, Tkachenko MV, Babanina MYu, Volchenko HV, Kitura YeM, Ivanytskyi IV. [Insulin resistance in systemic lupus erythematosus]. Family medicine. European practices. 2024;2:49-54. Ukrainian. doi: https://doi.org/10.30841/2786-720X.2.2024.307530
Baumann P, Völkl A, Bäuerle M, Schmidmaier R, Oduncu FS. Aplastic crisis as primary manifestation of systemic lupus erythematosus. Onkologie. 2011;34(8-9):452-4. doi: https://doi.org/10.1159/000331069
Ungprasert P, Chowdhary VR, Davis MD, Makol A. Autoimmune myelofibrosis with pancytopenia as a presenting manifestation of systemic lupus erythematosus responsive to mycophenolate mofetil. Lupus. 2016;25(4):427-30. doi: https://doi.org/10.1177/0961203315615221
Piga M, Arnaud L. The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand? J Clin Med. 2021;10(2):243. doi: https://doi.org/10.3390/jcm10020243
Hailu GT, Hussen SU, Getachew S, Berha AB. Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. BMC Nephrol. 2022;23(1):214. doi: https://doi.org/10.1186/s12882-022-02846-z
Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7.
doi: https://doi.org/10.1038/s41572-019-0141-9
Wallace ZS, Naden RP, Chari S, Choi HK, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2020;79(1):77-87. doi: https://doi.org/10.1136/annrheumdis-2019-216561
Heikki Ju. [Guideline 00446. Systemic lupus erythematosus (SLE)]. [Internet]. 2017 [cited 2024 Dec 13]. 17 p. Ukrainian. Available from: http://guidelines.moz.gov.ua/documents/2918
Kostopoulou M, Fanouriakis A, Cheema K, Boletis J, Bertsias G, Jayne D, et al. Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. RMD Open. 2020;6(2):e001263.
doi: https://doi.org/10.1136/rmdopen-2020-001263
Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-23. doi: https://doi.org/10.1136/annrheumdis-2020-216924
[KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases]. Kidneys. 2021;10(4):201-28. Ukrainian. doi: https://doi.org/10.22141/2307-1257.10.4.2021.247896С
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: https://doi.org/10.1136/ard-2023-224762
[KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis]. Kidneys. 2024;13(1):18-25. Ukrainian. doi: https://doi.org/10.22141/2307-1257.13.1.2024.437
Ivanov DD. [Chronic kidney disease: differential tactics of renoprotection]. Ukr Med J [Internet]. 2018 [cited 2024 Dec 13];2(124):1-5. Ukrainian. Available from: https://umj.com.ua/uk/publikatsia-124335-hronichna-hvoroba-nirok-diferentsijna-taktika-renoprotektsiyi
Siniscalchi С, Rossetti P, Carolla G, Micco P, Stella A, Riva M. A review on management of antiphos-pholipid syndrome in clinical practice. Ital J Med. 2023;17(2):1649. doi: https://doi.org/10.4081/itjm.2023.1649
Тaran OI. [Thrombotic thrombocytopenic micro-angiopathy]. Kidneys. 2022;2(4):66-9. Ukrainian. doi: https://doi.org/10.22141/2307-1257.0.2.04.2013.85358
Kobeliatskyi YuYu. [Intensive care of haemolytic uremic syndrome in pregnant women]. Surg. Orthop. Traumatol. Int care [Internet]. 2021 [cited 2024 Dec 23];2(45):14-5. Ukrainian. Available from: https://health-ua.com/multimedia/6/5/8/2/0/1624020515.pdf
Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN. Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials. J Rheumatol. 2016;43(8):1503-9. doi: https://doi.org/10.3899/jrheum.150671
Shuba NM. [Emergency conditions in patients with rheumatic diseases: modern approaches to treatment]. Ukr J Rheumatol [Internet]. 2009 [cited 2024 Dec 13];3(37):41-8. Ukrainian. Available from: https://www.rheumatology.kiev.ua/wp/wp-content/uploads/magazine/37/41.pdf
Kiss E, Tarr T, Soltész P, Szegedi G. [Crisis states in systemic lupus erythematosus]. Orv Hetil. 2006;147(51):2469-73. Hungarian.
Kovalenko VM, Rekalov DH, Yatsyshchyn RI, Holovach IYu, Stanislavchuk MA, Ter-Vartanian SKh, et al. [Systemic lupus erythematosus. Clinical guidelines]. Kyiv; 2020. 76 p. Ukrainian.
Katerenchuk IP, Tkachenko LA, Yarmola TI, Talash VV. Microscopic polyangiitis – a view of the problem through the lens of a nephrologist. Wiad Lek. 2021;74(4):1024-31. doi: https://doi.org/10.36740/WLek202104140
Yarmola TI, Gutsalenko OO, Katerenchuk IP, Tkachenko LA, Kostrikova YА, Talash VV. Microscopic polyangiitis hiding behind the mask of COVID-19: A case series and minireview. Ukr J Nephrol Dial. 2023;2(78):5-21. doi: https://doi.org/10.31450/ukrjnd.2(78).2023.02
Hsu T, Nguyen P, Petronic-Rosic V. A case of systemic lupus erythematosus with cutaneous granu-lomatous vasculitis. JAAD Case Rep. 2022;21:93-6. doi: https://doi.org/10.1016/j.jdcr.2022.01.006
Botero B JD, Bernal-Macías S, Celis P CA, Las-so A JI, Rodríguez J, Arias Álvarez L, et al. Systemic lupus erythematosus/ANCA-associated vasculitis overlap: An explanation for atypical lupus manifestation. Lupus. 2022;31(4):495-9. doi: https://doi.org/10.1177/09612033221084519
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheu-matology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151-9. doi: https://doi.org/10.1136/annrheumdis-2018-214819
Abrahamovych UO, Abrahamovych OO, Tsyhanyk LV, Farmaha ML, Synenkyi OV. [A Method to Determine Functional Class of Systemic Lupus Erythe-matosus in Patients]. World Sci. 2020;2(5(57):10-9. Ukrainian. doi: https://doi.org/10.31435/rsglobal_ws/31052020/7076
National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis. 2012;60(5):850-86. doi: https://doi.org/10.1053/j.ajkd.2012.07.005
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl [Internet]. 2012 [cited 2024 Sept 11];3(1):1-150. Available from: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
Yu C, Li P, Dang X, Zhang X, Mao Y, Chen X. Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun. 2022;132:102871. doi: https://doi.org/10.1016/j.jaut.2022.102871
Julkunen H. Guideline 00446. Systemic lupus erythematosus (SLE) [Internet]. 2017 [updated 2017 Jul 31; cited 2024 Dec 13]. Available from: https://guidelines.moz.gov.ua/documents/3299
Kato K, Kawamura T, Terashima R, Tsuchiya Y, Takahashi Y, Kasai K, et al. A Case of Systemic Lupus Erythematosus/Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome with Dissociated Pathological and Immunological Findings. Case Rep Nephrol. 2020;2020:5698708. doi: https://doi.org/10.1155/2020/5698708
Rossi GP, Bisogni V, Rossitto G, Maiolino G, Cesari M, Zhu R, et al. Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension. High Blood Press Cardiovasc Prev. 2020;27(6):547-60. doi: https://doi.org/10.1007/s40292-020-00415-9
Soyuöz A, Karadağ Ö, Karaağaç T, Kılıç L, Bilgen ŞA, Özcebe Oİ. Therapeutic plasma exchange for refractory SLE: A comparison of outcomes between different sub-phenotypes. Eur J Rheumatol. 2018;5(1):32-6. doi: https://doi.org/10.5152/eurjrheum.2017.17088
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. doi: https://doi.org/10.1161/HYPERTENSIONAHA.120.15026
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3):559-69. doi: https://doi.org/10.1016/j.kint.2020.10.026
Kaidashev I, Shlykova O, Izmailova O, Toru-bara O, Yushchenko Y, Tyshkovska T, et al. Host gene variability and SARS-CoV-2 infection: A review article. Heliyon. 2021;7(8):e07863. doi: https://doi.org/10.1016/j.heliyon.2021.e07863
Honkanen E. [Guideline 00225. Acute kidney injury]. [Internet]. 2017 [cited 2024 Sept 11]. 9 p. Ukrainian. Available from: https//guidelines.moz.gov.ua/documents/3113
Tarasenko SO, Dubrov SO, Suslov HH. [Diagnostic criteria for disseminated intravascular coagulation syndrome and sepsis-induced coagulopathy]. Pain, Anaesth & Int Care. 2021;2(95):25-38. Ukrainian. doi: https://doi.org/10.25284/2519-2078.2(95).2021.238302
Yaremenko OB, Sydorova AO. [Hemophagocytic syndrome in a patient with paniculitis: a case report]. Ukr J Rheumatol. 2021;2(84):1-5. Ukrainian. doi: https://doi.org/10.32471/rheumatology.2707-6970.84.16101
Driouach S, Mounir A, Elkhader S, Zinebi A, Moudden MK. [Pancytopenia secondary to autoimmune myelofibrosis revealing a male case of systemic lupus]. Ann Biol Clin (Paris). 2019;77(3):327-30. French. doi: https://doi.org/10.1684/abc.2019.1443
Protsenko HO, Dubas VV. [Analysis of delayed diagnosis in systemic lupus erythematosus]. Ukr J Rheumatol. 2022;1(87):1-6. Ukrainian. doi: https://doi.org/10.32471/rheumatology.2707-6970.87.16747
Solhjoo M, Goyal A, Chauhan K. Drug-Induced Lupus Erythematosus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [updated 2023 Apr 3; cited 2024 Nov 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441889
Aaltonen S. [Guideline 00229. Glomerulo-nephrites]. [Internet]. 2017 [updated 2017 May 22; cited 2024 Dec 13]. Ukrainian. Available from: https://guidelines.moz.gov.ua/documents/3117
Ahn SS, Yoon T, Song JJ, Park YB, Lee SW. Serum adipokine profiles in patients with microscopic polyangiitis and granulomatosis with polyangiitis: An exploratory analysis. PLoS One. 2021;16(7):e0254226. doi: https://doi.org/10.1371/journal.pone.0254226
Banos A, Thomas K, Garantziotis P, Filia A, Malissovas N, Pieta A, et al. The genomic landscape of ANCA-associated vasculitis: Distinct transcriptional signatures, molecular endotypes and comparison with sys¬temic lupus erythematosus. Front Immunol. 2023;14:1072598. doi: https://doi.org/10.3389/fimmu.2023.1072598
Khil J, Nguyen TM, Troxell ML, Zheng S. Systemic Lupus Erythematosus and ANCA-Associated Vas-culitis Overlap Syndrome: A Case Report. Kidney Med. 2022;4(11):100544. doi: https://doi.org/10.1016/j.xkme.2022.100544
Borzykh O, Belan O, Mormol I, Avramenko Y, Іengalychev T, Markina T. Characteristics of the course of leucocytoclastic vasculitis with skin lesions. analysis of clinical cases. Med and Ecol Probl. 2023;27(1-2):35-41. doi: https://doi.org/10.31718/mep.2023.27.1-2.07
Mucke J, Aringer M. [EULAR recommendations 2023 on the treatment of systemic lupus erythematosus-Implications for treatment in Germany]. Z Rheumatol. 2024;83(6):431-8. German. doi: https://doi.org/10.1007/s00393-024-01544-5
Velichuk A. [Systemic lupus erythematosus. A clinical case]. In: Topical issues of clinical medicine: Collection of materials of the All-Ukrainian scientific and practical conference of interns; 2023 May 25; Poltava, UA [Internet]. Poltava; 2023 [cited 2024 Oct 3]. p. 103-4. Ukrainian. Available from: https://repository.pdmu.edu.ua/handle/123456789/21453
Mormol I, Borzykh O, Gerasymenko N, Esanu C, Ozarchuk L. [Lesions of the hematopoietic system in a patient with systemic lupus erythematosus and the effectiveness of treatment with mycophenolate mofetil]. Med and Ecol Probl. 2022;26(5-6):7-10. Ukrainian. doi: https://doi.org/10.31718/mep.2022.26.5-6.02
Newman K, Owlia MB, El-Hemaidi I, Akhtari M. Management of immune cytopenias in patients with systemic lupus erythematosus – Old and new. Autoimmun Rev. 2013;12(7):784-91. doi: https://doi.org/10.1016/j.autrev.2013.02.001
Shoenfeld Y, Zandman-Goddard G, Levy Y. Comment on published article in Lupus: Autoimmune myelofibrosis with pancytopenia as a presenting ma-nifestation of systemic lupus erythematosus responsive to mycophenolate mofetil; IVIG in myelofibrosis in SLE. Lupus. 2017;26(2):224. doi: https://doi.org/10.1177/0961203316662725
Wibowo T, Kawada S, Ishida Y, Yoshimine Y, Ishikawa N, Kawamoto K, et al. Autoimmune myelo-fibrosis associated with systemic lupus erythematosus: a case report. Mod Rheumatol Case Rep. 2020;4(1):28-33. doi: https://doi.org/10.1080/24725625.2019.1650697
Üsküdar Cansu D, Üsküdar Teke H, Işiksoy S, Korkmaz C. Bone marow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis. Int J Rheum Dis. 2018;21(5):1049-59. doi: https://doi.org/10.1111/1756-185X.13308
Putra RS, Najirman. Treatment of Systemic Lupus Erythematosus with Anti SSA and SSB Positive Pregnancies. Biosmed. 2022;6(3):1523-9. doi: https://doi.org/10.37275/bsm.v6i3.470
Joy GM, Arbiv OA, Wong CK, Lok SD, Ad-derley NA, Dobosz KM, et al. Prevalence, imaging pat-terns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev. 2023;32(167):220210. doi: https://doi.org/10.1183/16000617.0210-2022
Kanapathy A, Nik Jaafar NR, Shaharir SS, Chan LF, Rozita M, Ch'ng SS. Prevalence of cognitive impairment using the Montreal Cognitive Assessment questionnaire among patients with systemic lupus erythematosus: a cross-sectional study at two tertiary centres in Malaysia. Lupus. 2019;28(7):854-61. doi: https://doi.org/10.1177/0961203319852153
Koliadenko DI, Yaremenko OB, Nahirna MI. [Neuropsychiatric manifestations in patients with systemic lupus erythematosus: prevalence, clinical and laboratory as¬sociations]. Ukr J Rheumatol. 2023;1(91):1-7. Ukrainian. doi: https://doi.org/10.32471/rheumatology.2707-6970.91.17688
Abrahamovych U, Abrahamovych О, Nadashkevich О, Farmaha М, Kobak L. Pathogenetic Association of Digestive System Lesions with Systemic Lupus Erythematosus: Characteristics and Prevalence. PMGP. 2020;5(1):e0501225. doi: https://doi.org/10.26766/pmgp.v5i1.225
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Annals of the Rheumatic Diseases. Ann Rheum Dis. 2019;78(6):736-45. doi: https://doi.org/10.1136/annrheumdis-2019-215089
Prokhorov EV, Borysova TP. [Features of the current course and therapy of systemic lupus erythe-matosus in children and adolescents]. Child Health. 2007;2(5):60-6. Russian.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-28. doi: https://doi.org/10.1056/NEJMoa2001180
Fanouriakis A, Bertsias G, Boumpas DT. Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythe¬matosus' by Wu et al. Ann Rheum Dis. 2022;81(5):e76. doi: https://doi.org/10.1136/annrheumdis-2020-217804
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Medicni perspektivi

This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.



